EUVIMEDEUVIMED entdecken
Editorial

Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?

Raheel Ahmed, Aimen Shafiq, Mushood Ahmed

British Journal of Hospital Medicine · 24.01.2025 · 86 (1) · 1-6

DOI: 10.12968/hmed.2024.0712 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Hospital Medicine, erschienen am 24.01.2025. Verfasst von Raheel Ahmed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Royal Brompton Hospital, Part of Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of once-weekly insulin icodec is a promising development in the care of individuals with diabetes. These once-weekly formulations aimed to improve patient adherence and quality of life for patients who find daily injection administration challenging. Insulin icodec has demonstrated comparable glycemic control to conventionally used daily basal insulins, such as insulin glargine and degludec, in the ONWARDS clinical trials. This approach is aligned with patient-centred guidelines, offers better convenience, and can potentially improve adherence, particularly among older adults with type 2 diabetes and those experiencing distress related to frequent injection administration. However, several challenges persist before widespread adoption is feasible. One main concern is ensuring consistent insulin levels over a full week as fluctuations can lead to an increased risk of hypo- or hyperglycemia. Education, precise dosing, and further research are required to ensure long-term efficacy and safety. Moreover, logistical hurdles, including production costs and supply chain complexities need to be addressed especially in low-resource settings. Future studies should evaluate the broader health impacts of weekly insulin, including cardiovascular outcomes, quality of life, and personalized dosing strategies. Making weekly insulin safe, affordable, and widely available is important to fully realize its potential in diabetes management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinHumansDrug Administration ScheduleInsulin, Long-ActingMedication AdherenceQuality of Life

Stichwörter der Autor:innen

diabetesinsulin

Substanzen

Hypoglycemic AgentsInsulinInsulin, Long-Acting

Autor:innen und Institutionen

  • Department of Cardiology, Royal Brompton Hospital, Part of Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Department of Cardiology, National Heart and Lung Institute, Imperial College London, London, UK.
  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.

Zitieren

APA

Ahmed, R., Shafiq, A., & Ahmed, M. (2025). Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?. British Journal of Hospital Medicine, 86(1), 1-6. https://doi.org/10.12968/hmed.2024.0712

Vancouver

Ahmed R, Shafiq A, Ahmed M. Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?. British Journal of Hospital Medicine. 2025;86(1):1-6. doi:10.12968/hmed.2024.0712

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Raheel and Shafiq, Aimen and Ahmed, Mushood},
  title = {Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?},
  journal = {British Journal of Hospital Medicine},
  year = {2025},
  volume = {86},
  number = {1},
  pages = {1--6},
  doi = {10.12968/hmed.2024.0712}
}
Kostenlos starten →